文献速递多重用药认知障碍与谵妄老年综合评估

美国养老院居民阿片类药物与增效剂合用:全国患病率与相关因素

Use of Opioids and Opioid Potentiators Among Nursing Home Residents in the United States: National Prevalence and Correlates.
PubMed 文献 · J Am Geriatr Soc · 2026-10-28

基于2019年美国养老院最小数据集3.0与Part D理赔等全国代表性数据的横断面研究,纳入135,347名长期照护居民,评估阿片类药物使用及与增效剂(苯二氮䓬类、非苯二氮䓬类、加巴喷丁类)合用的患病率及相关因素。结果显示24.0%有阿片类处方,其中52.0%合用增效剂,长期使用仍普遍;疼痛和焦虑等合并症与使用正相关,认知障碍和痴呆与使用负相关。

要点

  • 长期照护居民中24.0%有阿片类处方,11.4%为长期使用(≥90天)。
  • 阿片类使用者中52.0%合用增效剂,最常见为加巴喷丁类。
  • 认知障碍和痴呆与阿片类使用及合用增效剂的 odds 较低相关。

核心结论

  • 老年养老院居民中长期阿片类使用仍普遍,阿片类与增效剂合用亦普遍,需强调更安全的阿片相关用药。

研究设计与样本

  • 横断面研究,使用2019年全国代表性数据:最小数据集3.0(MDS 3.0)链接Part D理赔及其他数据源。
  • 纳入135,347名长期照护居民,按索引评估后120天内阿片类使用时长分为短期(≤30天)、中期(31-89天)和长期(≥90天)。

主要发现

  • 135,347名长期照护居民中32,550名(24.0%)有任何阿片类处方。
  • 7.1%为短期阿片类使用者,5.5%为中期使用者,11.4%为长期使用者。
  • 阿片类使用者中52.0%合用任何阿片类增效剂。
  • 最常使用的增效剂类别为加巴喷丁类,其次为苯二氮䓬类和非苯二氮䓬类。
  • 疼痛和其他合并症(如焦虑)与上述使用显著相关(p < 0.001);认知障碍和痴呆与阿片类使用及合用增效剂的 odds 较低相关(p < 0.01)。

临床怎么用

  • 在长期照护机构中应强调更安全的阿片相关用药,考虑非阿片类镇痛药和物理治疗等替代方案。
  • 对使用阿片类的居民应定期进行药物审查和减处方。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Concurrent use of opioids and opioid potentiators (i.e., benzodiazepines, non-benzodiazepines, and gabapentinoids) can elevate the risks of potential harms (e.g., hospitalizations and deaths). However, no study has yet examined the co-use of opioids and opioid potentiators in US nursing homes. METHODS: We used nationally-representative data in 2019 from Minimum Data Set 3.0 (MDS 3.0) linked with Part D claims and other data sources, and measured length of opioid use in the 120 days from the index assessment (short-term users: ≤ 30 days; medium-term users: 31-89 days, and long-term users: ≥ 90 days). In this cross-sectional study design, we estimated prevalence of opioid use and co-use of opioids and opioid potentiators by duration of opioid use. We also estimated resident- and facility-level factors associated with opioid use and co-use of opioids and opioid potentiators in long-stay nursing home residents. RESULTS: Of 135,347 long-stay nursing home residents, 32,550 (24.0%) had any opioid prescriptions. 7.1% were short-term opioid users, 5.5% were mid-term opioid users, and 11.4% were long-term opioid users. Among opioid users, 52.0% also had any opioid potentiators. The most frequently used potentiator class was gabapentinoids, followed by benzodiazepines and non-benzodiazepines. Pain and other comorbid conditions (e.g., anxiety) were significantly associated with such uses (p < 0.001). Cognitive impairment and dementia were associated with lower odds of opioid use and co-use of opioid-potentiators (p < 0.01). CONCLUSIONS: Long-term opioid use in older nursing home residents remains prevalent. The co-use of opioids and opioid potentiators is also prevalent in this population. Because co-use of opioid-potentiators can pose elevated risks for potentially avoidable harms, safer opioid-related medication use needs to be emphasized in long-term care settings. Alternatives to opioid use (e.g., non-opioid pain medications and physical therapy) should be considered, and regular medication reviews and deprescribing efforts will be critical in residents taking opioids in nursing home settings.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Jiao, Channa, Wasolua, et al. Use of Opioids and Opioid Potentiators Among Nursing Home Residents in the United States: National Prevalence and Correlates. J Am Geriatr Soc. 2026. PMID: 42951674. doi:10.1111/jgs.70808

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。